In the early years of the new millennium, as China’s healthcare market was beginning to take off and western drug companies sought to cash in, a Pfizer marketing manager sent a message to a colleague.
He said he would authorise payment for two Chinese doctors to attend a scientific conference in Australia, but only on condition that they promised to “use no less than 4,200 injections a year” and to prescribe a Pfizer product to “more than 80 per cent” of their patients.
The tactics employed by local staff of the US pharmaceuticals group were not the exception.
您已閱讀13%（564字），剩余87%（3939字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。